title: [Clinical efficacy of fosfomycin in combination with sulbactam/cefoperazone in the treatment of severe infections complicated to blood dyscrasia. Working Group of Kanto Combination Therapy for FOM + SBT/CPZ].
abstract: In the treatment of severe infections complicated to blood dyscrasia, the efficacy and usefulness of fosfomycin (FOM) in combination with sulbactam (SBT)/cefoperazone (CPZ) were compared between patients receiving FOM in the first followed by SBT/CPZ (Group A) and those receiving both drugs simultaneously (Group B). The following results were obtained. 1. The efficacy rate was 56.3% for Group A and 47.9% for Group B, with no significant difference. 2. The efficacy for patients suspected of the presence of septicemia, the efficacy rate was 57.9% for Group A and 54.3% for Group B, with no significant difference. 3. As for underlying disease, patients with acute myelogenous leukemia were most prevailing. In these patients, the efficacy rate was 57.1% for Group A and 27.3% for Group B, with no statistically significant difference. However, the efficacy rate tended to be higher in Group A. 4. The administration of antibiotics was effective to restore the neutrophil count to 501/microliters or higher in 77.8% and 45.5% of the cases for Groups A and B, respectively, with significantly higher efficacy for Group A. 5. In the safety evaluation a total of 115 cases were included. Side effects and laboratory abnormalities were seen in 3 cases each, but none of them were serious in degree. From these results, it was confirmed that the combination therapy consisting of administration of FOM followed by SBT/CPZ with some interval is effective for severe infections complicated to blood dyscrasia.
authors.affiliation: Department of Laboratory Medicine, Faculty of Medicine, University of Tokyo.
authors.forename: K
authors.initials: K
authors.lastname: Kitamura
authors.forename: H
authors.initials: H
authors.lastname: Hirai
authors.forename: N
authors.initials: N
authors.lastname: Hosoya
authors.forename: M
authors.initials: M
authors.lastname: Sugai
authors.forename: M
authors.initials: M
authors.lastname: Karasawa
authors.forename: T
authors.initials: T
authors.lastname: Naruse
authors.forename: Y
authors.initials: Y
authors.lastname: Miura
authors.forename: K
authors.initials: K
authors.lastname: Ohmine
authors.forename: S
authors.initials: S
authors.lastname: Takagi
authors.forename: K
authors.initials: K
authors.lastname: Hirashima
authors.forename: M
authors.initials: M
authors.lastname: Bessho
authors.forename: M
authors.initials: M
authors.lastname: Fukuda
authors.forename: N
authors.initials: N
authors.lastname: Kawai
authors.forename: K
authors.initials: K
authors.lastname: Dan
authors.forename: E
authors.initials: E
authors.lastname: Ann
authors.forename: T
authors.initials: T
authors.lastname: Hoshino
authors.forename: K
authors.initials: K
authors.lastname: Oshimi
authors.forename: M
authors.initials: M
authors.lastname: Noguchi
authors.forename: M
authors.initials: M
authors.lastname: Egashira
authors.forename: Y
authors.initials: Y
authors.lastname: Ikeda
authors.forename: M
authors.initials: M
authors.lastname: Kizaki
authors.forename: K
authors.initials: K
authors.lastname: Toyama
authors.forename: K
authors.initials: K
authors.lastname: Miyazawa
authors.forename: M
authors.initials: M
authors.lastname: Nagasu
authors.forename: A
authors.initials: A
authors.lastname: Hirasawa
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D002438:Cefoperazone / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005578:Fosfomycin / Q000008:administration & dosage*; D006402:Hematologic Diseases / Q000150:complications*; D006801:Humans; D007239:Infections / Q000188:drug therapy*; D013407:Sulbactam / Q000008:administration & dosage*
chemical_list: D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D005578:Fosfomycin; D002438:Cefoperazone; C057923:sulperazone; D013407:Sulbactam